Cargando…

Amlamax™ in the Management of Dyslipidemia in Humans

Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing to...

Descripción completa

Detalles Bibliográficos
Autores principales: Antony, B., Merina, B., Sheeba, V.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792547/
https://www.ncbi.nlm.nih.gov/pubmed/20046781
http://dx.doi.org/10.4103/0250-474X.44604
_version_ 1782175254974562304
author Antony, B.
Merina, B.
Sheeba, V.
author_facet Antony, B.
Merina, B.
Sheeba, V.
author_sort Antony, B.
collection PubMed
description Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing total cholesterol. These molecules act by inhibiting the HMG CoA reductase enzyme thereby interfering with the synthesis of cholesterol. But statins reduce all the cholesterol including HDL cholesterol. Long term drug vigilance activity has revealed serious side effects of tendinopathy and related musculoskeletal disorders in some of the subjects. In an effort to manage hypercholesterolemia without serious side effects in a natural way we had tried the use of Amlamax™ a reconstituted, purified, standardized dried extract of amla (Emblica officinalis) containing 30% ellagitannins with other hydrolysable tannins on humans. We report the hitherto unobserved significant elevation of HDL cholesterol by the administration of Amlamax™
format Text
id pubmed-2792547
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-27925472009-12-14 Amlamax™ in the Management of Dyslipidemia in Humans Antony, B. Merina, B. Sheeba, V. Indian J Pharm Sci Short Communications Hypercholesterolemia is the major cause of cardiovascular diseases leading to myocardial infarctions leading to considerable morbidity and mortality. During the past decade a group of molecules referred to as statins such as simvastatin, atrovastatin have been tried with great success in reducing total cholesterol. These molecules act by inhibiting the HMG CoA reductase enzyme thereby interfering with the synthesis of cholesterol. But statins reduce all the cholesterol including HDL cholesterol. Long term drug vigilance activity has revealed serious side effects of tendinopathy and related musculoskeletal disorders in some of the subjects. In an effort to manage hypercholesterolemia without serious side effects in a natural way we had tried the use of Amlamax™ a reconstituted, purified, standardized dried extract of amla (Emblica officinalis) containing 30% ellagitannins with other hydrolysable tannins on humans. We report the hitherto unobserved significant elevation of HDL cholesterol by the administration of Amlamax™ Medknow Publications 2008 /pmc/articles/PMC2792547/ /pubmed/20046781 http://dx.doi.org/10.4103/0250-474X.44604 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Antony, B.
Merina, B.
Sheeba, V.
Amlamax™ in the Management of Dyslipidemia in Humans
title Amlamax™ in the Management of Dyslipidemia in Humans
title_full Amlamax™ in the Management of Dyslipidemia in Humans
title_fullStr Amlamax™ in the Management of Dyslipidemia in Humans
title_full_unstemmed Amlamax™ in the Management of Dyslipidemia in Humans
title_short Amlamax™ in the Management of Dyslipidemia in Humans
title_sort amlamax™ in the management of dyslipidemia in humans
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792547/
https://www.ncbi.nlm.nih.gov/pubmed/20046781
http://dx.doi.org/10.4103/0250-474X.44604
work_keys_str_mv AT antonyb amlamaxinthemanagementofdyslipidemiainhumans
AT merinab amlamaxinthemanagementofdyslipidemiainhumans
AT sheebav amlamaxinthemanagementofdyslipidemiainhumans